Virtual Library
Start Your Search
P. Smičková
Author of
-
+
P1.04 - Poster Session with Presenters Present (ID 456)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Pulmonology
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.04-008 - Tumor Pentaplicity - Case Report (ID 4658)
14:30 - 15:45 | Author(s): P. Smičková
- Abstract
Background:
Metachronic tumor duplicity is a relatively common phenomenon, often related to mutagenic effects of some types of antitumor therapy. However, idiopathic tumor multiplicity is rare. We present the case report of a patient, who developed five different malignant tumors in fifteen years horizon.
Methods:
Case report
Results:
66-year old patient was diagnosed renal cell carcinoma in year 2001 with subsequent nephrectomy. During follow-up, a coin lesion was recognized on chest x-ray, histologically and radiologically verified as stage IA pulmonary adenocarcinoma. Patient underwent successful right lower lobectomy. In 2010 colorectal carcinoma was diagnosed followed by non-invasive papillocarcinoma of urinary bladder in 2012. All these tumors were treated curatively. In 2014 a new mass appeared on chest x-ray. Repeated bronchoscopy failed to obtain valid histological sample. The positron emission tomography revealed malignancy suspicion and excluded the disseminated disease. Surgical resection was performed. Peroperative histology reported carcinoma of uncertain type and surgeon decided for completion of pulmonectomy. However, final histological report showed small-cell lung cancer (pT2apN2Mx). Despite adjuvant chemotherapy given the patient developed distant metastases and died subsequently due to tumor progression in February 2016.
Conclusion:
Tumor pentaplicity is a clinical situation with rare occurrence. Our patient didn´t receive chemotherapy until 2010 (adjuvant chemotherapy after radical colorectal carcinoma surgery), so there could be no influence of the first three malignancies therapy. We did not find tumor occurrence in the family, no external risk factor, the patient fits in none of defined hereditary cancer predisposition disorder. Detection of common driver mutations in all five tumors is running. The long term survival is supporting the idea of a careful follow up and shows advances in current oncological treatment.
